Estimaciones de analistas de Wall Street para Puma Biotechnology, Inc. (PBYI): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 8 |
| Mantener | 8 |
| Venta | 4 |
| Venta fuerte | 0 |
| Analistas totales | 20 |
| Calificación media (1-5) | 0.20 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-05 | $0.11 | ||
| 2026-08-06 | $0.19 | $0.04 | +375.0% |
| 2026-05-07 | $-0.04 | $-0.13 | +69.2% |
| 2026-02-26 | $0.29 | $0.24 | +20.8% |
| 2025-11-06 | $0.21 | $0.09 | +133.3% |
| 2025-08-07 | $0.15 | $0.11 | +36.4% |
| 2025-05-08 | $0.10 | $0.02 | +400.0% |
| 2025-02-27 | $0.43 | $0.10 | +330.0% |
Ratios de valoración
| Ratio P/E | 16.72 |
| Precio / Valor contable | 3.30 |
| EV / EBITDA | 9.07 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | $27.7M | $251.0M | $272.3M | $225.1M | $253.2M | $228.0M | $235.6M | $230.5M | $228.4M |
| Coste de Ventas | $1.1M | $5.6M | $34.6M | $36.8M | $39.4M | $63.7M | $55.1M | $62.7M | $64.4M | $58.2M |
| Beneficio Bruto | -$1.1M | $22.1M | $216.4M | $235.4M | $185.7M | $189.5M | $172.9M | $173.0M | $166.1M | $170.2M |
| I+D | $222.8M | $207.8M | $164.9M | $132.9M | $97.7M | $71.9M | $52.2M | $50.4M | $54.9M | $62.1M |
| Generales y Administrativos | $53.8M | $106.7M | $146.2M | $141.6M | $118.5M | $116.3M | $90.0M | $89.3M | $80.2M | $71.2M |
| Gastos Operativos | $276.6M | $314.5M | $311.1M | $311.0M | $216.1M | $188.2M | $149.2M | $140.3M | $135.1M | $132.9M |
| Beneficio Operativo | -$276.6M | -$292.4M | -$94.7M | -$75.6M | -$30.4M | $1.3M | $23.7M | $32.6M | $31.0M | $37.3M |
| EBITDA | -$275.4M | -$288.4M | -$95.2M | -$52.4M | -$35.7M | -$4.7M | $21.9M | $47.5M | $48.1M | $53.3M |
| Gastos por Intereses | $958000 | $720000 | $11.0M | $15.0M | $14.0M | $12.8M | $11.6M | $13.3M | $12.5M | $6.6M |
| Beneficio Antes de Impuestos | -$276.0M | -$292.0M | -$113.6M | -$75.5M | -$59.8M | -$28.8M | $457000 | $22.7M | $24.1M | $35.8M |
| Impuestos | -$2.1M | -$2.2M | -$7.9M | $53000 | $207000 | $324000 | $455000 | $1.1M | -$6.2M | $4.7M |
| Beneficio Neto | -$276.0M | -$292.0M | -$113.6M | -$75.6M | -$60.0M | -$29.1M | $2000 | $21.6M | $30.3M | $31.1M |
| BPA | $-8.29 | $-7.86 | $-2.99 | $-2.13 | $-1.52 | $-0.72 | $0.02 | $0.46 | $0.62 | $0.62 |
| BPA Diluido | $-8.29 | $-7.86 | $-2.99 | $-2.13 | $-1.52 | $-0.72 | $0.02 | $0.45 | $0.62 | $0.61 |
| Acciones en Circulación (Diluidas) | $33.3M | $37.2M | $37.9M | $38.8M | $39.6M | $40.6M | $44.9M | $47.6M | $49.1M | $50.7M |
Precio
| Precio | $9.39 |
| Capitalización | $478M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ABEO · ALLO · ARCT · AVIR · ELDN · HUMA · SGMT
Explorar sector: Healthcare · Biotechnology
Más secciones de PBYI: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones